This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Antares Pharma Reports Second Quarter 2013 Operating And Financial Results

Stocks in this article: ATRS

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the second quarter ended June 30, 2013.

Quarter and Recent Highlights

  • OTREXUP™ development program is on track with anticipated PDUFA date of October 14, 2013.
  • Granted product specific U.S. patent 8,480,631 for OTREXUP™.
  • Completed recruitment of a commercial team with significant rheumatology and product launch experience.
  • Expanded intellectual property portfolio with 43 patents filed and 9 patents issued in the past 18 months, including recently issued QS Device U.S. patent 8,496,619.
  • Continued to ship VIBEX™ auto injector devices to Teva for pre-launch quantities of Teva’s generic epinephrine auto injector product.
  • Added Marvin Samson and Robert Roche Jr. to the Board of Directors, both experienced pharmaceutical executives with expertise in injectable manufacturing, delivery systems, commercialization and product launches.
  • Total revenues increased 29% to $5.8 million and product revenues increased 41% to $4.5 million compared to the second quarter of 2012.
  • Ended the quarter with $75.0 million in cash and investments and no debt.

Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “I am pleased to report that Antares made significant progress on many fronts during the second quarter as we transition to a specialty pharmaceutical company. Our primary focus is on the OTREXUP™ commercialization planned for early 2014. We recently completed the recruitment of an experienced in-house sales and marketing team with significant 'Big Pharma' product launch experience in the rheumatology market segment.” Dr. Wotton continued, “We also progressed our QST program for Testosterone Replacement Therapy and anticipate dosing the first patients in this coming quarter, which keeps this program on track for a potential launch in 2016.”

Second Quarter and First Half Results

Total revenues were $5.8 million and $4.5 million for the three months ended June 30, 2013 and 2012, respectively, an increase of 29%. For the six months ended June 30, 2013, the Company’s total revenue was $10.4 million compared to $11.4 million in the first six months of 2012. Product sales were $4.5 million in the second quarter of 2013 compared to $3.2 million in 2012, an increase of 41%. For the six months ended June 30, 2013, product sales increased 23% to $7.0 million compared to $5.7 million in the prior year. The product sales increases were primarily due to sales to Teva of pre-launch quantities of our Vibex™ auto injector for Teva’s generic epinephrine auto injector product.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs